InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.87%
)
US TECH 100
16,787.20
(
0.21%
)
Dow Jones
38,239.98
(
0.67%
)
Brent Oil
86.70
(
0.33%
)
Bitcoin
66,298.41
(
-0.84%
)
Post# of 66
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

johnsyn

Send PM Follow Ignore
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

johnsyn

Re: None

Monday, 07/01/2013 3:14:44 PM

Monday, July 01, 2013 3:14:44 PM

Post# of 66
8:18 AM Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13 revenue guidance to $128-134M. The company now projects a wider net loss than previously expected however and also says it is temporarily suspending enrollment in its Ventana U.S. IDE clinical trial.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up